Hepatitis Delta Virus (HDV) is a defective RNA virus that requires concurrent or prior infection with hepatitis B virus (HBV) to replicate and cause disease. It is considered the most severe form of viral hepatitis, leading to faster progression to cirrhosis, liver failure, and hepatocellular carcinoma compared to HBV mono-infection. HDV infection occurs as co-infection (simultaneous acquisition of HBV and HDV) or superinfection (HDV in chronic HBV carriers). Symptoms include acute hepatitis (jaundice, fatigue, abdominal pain) and chronic progression with high mortality. Diagnosis relies on serological tests for anti-HDV antibodies and HDV RNA PCR. Treatment is limited, with pegylated interferon-alpha as the mainstay (low response rates). Bulevirtide (Hepcludex), an entry inhibitor approved in Europe, blocks viral entry and offers improved outcomes. Emerging therapies target tau pathology, though no cure exists.

Market Overview

The Europe hepatitis delta virus (HDV) infection market size was valued at USD 21.62 million in 2024 and is expected to reach USD 33.19 million by 2032, at a CAGR of 5.50% during the forecast period

The Europe hepatitis delta virus (HDV) infection market is experiencing growth due to improved diagnostics, increasing awareness of rare liver diseases, and the introduction of targeted therapies. The market encompasses diagnostic tests, antiviral drugs, supportive care, and emerging biologics. Europe leads globally in HDV research and treatment access, supported by regulatory frameworks, orphan drug incentives, and strong healthcare systems. While exact market size figures are detailed in the full paid report, the analysis highlights steady expansion driven by unmet medical needs in this rare but severe co-infection.

Market Segmentation

The market is segmented as follows:

• By Type: Acute HDV Infection, Chronic HDV Infection.
• By Diagnosis: Blood Tests (anti-HDV antibodies, HDV RNA), Liver Biopsy, Imaging, Others.
• By Treatment: Antiviral Therapy (pegylated interferon-alpha, bulevirtide), Liver Transplantation, Symptomatic Treatment, Others.
• By Drug Class: Interferons, Entry Inhibitors, Others.
• By Route of Administration: Injectable, Oral.
• By End-User: Hospitals, Specialty Clinics, Homecare, Others.
• By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others.

Chronic HDV and antiviral therapies dominate, reflecting the disease's progressive nature.

Key Market Drivers

• Rising diagnosis rates through improved screening in high-risk groups (e.g., injection drug users, immigrants from endemic areas).
• Regulatory approval and availability of bulevirtide (Hepcludex) in the EU, addressing unmet needs in chronic HDV.
• Increasing hepatitis B prevalence in certain populations, elevating HDV co-infection risks.
• Strong research funding and orphan drug incentives accelerating pipeline development.

Restraints and Challenges

• Extremely low disease prevalence limits large-scale clinical trials and commercial viability.
• High costs of specialized diagnostics and emerging therapies restrict access.
• Limited treatment efficacy with current options and diagnostic delays due to overlap with other liver diseases.
  
  Get Full Access Of The Report:
  https://www.databridgemarketresearch.com/reports/europe-hepatitis-delta-virus-hdv-infection-market

Opportunities

• Pipeline advancements in novel antivirals, siRNA-based therapies, and entry inhibitors.
• Expansion of screening programs in at-risk communities.
• Collaborations among academia, pharma, and advocacy groups for awareness and research.

Regional Insights

Germany dominates the Europe market due to advanced diagnostics, high R&D investment, and strong regulatory support. France and Italy contribute through established hepatology research and treatment centers. Growth is influenced by immigration patterns from HDV-endemic regions and improved testing in urban centers.

Major Market Players

Key companies include Gilead Sciences, Inc. (U.S., with bulevirtide), Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and others active in rare liver disease research.

Conclusion

The Europe HDV infection market, though niche due to the disease's rarity, is poised for growth through 2032, supported by diagnostic improvements and emerging therapies. Germany leads with advanced care systems. Opportunities in novel antivirals and screening will address unmet needs, offering hope for better management of this severe co-infection.

This summary is based on publicly available insights from the Data Bridge Market Research report overview as of late 2025. For detailed quantitative forecasts, financials, and custom analysis, refer to the full report at the original source.

Browse More Reports:

Global Imitation Jewellery Market
Global Beauty Devices Market
Global Matcha Tea Market
Global AI Meeting Assistants Market
Global Air Fryer Market
Global Mobile Device Management Market
Global Procedure Trays Market
Global Surgical Simulator Market
Global Atherosclerosis Market
Global Agriculture Chemical Packaging Market
Global Coffee and Tea Shop Market
Global Precision Aquaculture Market
Global Jute Bag Market
Global Utility Tractors Market
Global Cinnamon Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com